An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults With Primary Sclerosing Cholangitis (PSC)
Latest Information Update: 19 Jul 2024
At a glance
- Drugs A 3907 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Albireo Pharma
- 22 Jan 2024 Planned number of patients changed from 12 to 24.
- 29 Dec 2023 Planned End Date changed from 17 Jun 2024 to 14 Jun 2025.
- 29 Dec 2023 Planned primary completion date changed from 17 Jun 2024 to 14 Jun 2025.